安捷凯在线客服
- 客服:
- 电话: 13061953619
- 微信:
Enzaplatovir (BTA-C585) 是一种口服有效的融合 (fusion) 抑制剂,有潜力用于呼吸道合胞病毒 (RSV) 感染的研究。
Enzaplatovir (BTA-C585) is an orally bioavailable fusion inhibitor for respiratory syncytial virus (RSV) infection[1].
Respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) imposes a substantial medical burden. Enzaplatovir is a small-molecule RSV entry inhibitor[1].
[1]. Eric A F Sim?es, et al. Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infect Dis Ther. 2018 Mar;7(1):87-120.
动态评分
0.0